#United States #New York City #Parkinson's Disease #Mitsubishi Tanabe #IAPRD

Mitsubishi Tanabe Pharma America to Present at IAPRD 2025

Mitsubishi Tanabe Pharma America, Inc. (MTPA) has confirmed its participation in the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD), scheduled for May 7-10, 2025, in New York City. This prominent event aims to bring together healthcare professionals, researchers, and advocates to discuss the latest advancements in the understanding and treatment of Parkinson's disease (PD).

The highlight of MTPA's contributions to the congress will be two key poster presentations focusing on their investigational treatment, ND0612. This innovative therapy aims to manage motor fluctuations in patients with Parkinson’s disease through continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD).

Dr. Gustavo A. Suarez Zambrano, the Vice President of Medical Affairs at MTPA, expressed the company’s commitment to enhancing the understanding of Parkinson's disease. "We are pleased to present our ongoing research evaluating ND0612 in Parkinson's disease at IAPRD. This continued work reflects our dedication to expanding our knowledge of PD and sharing key study insights with the broader patient and scientific communities," he stated.

Presentation Details

During the congress, attendees will have the opportunity to view MTPA’s posters in the Exhibit and Poster Hall. Moreover, these presentations will be part of the Guided Poster Tour scheduled for May 10, 2025, from 8:00 AM to 9:00 AM EDT.

The two presentations will offer insights from the pivotal Phase 3 BouNDless trial (NCT04006210), which assesses the efficacy of ND0612 in individuals suffering from significant motor fluctuations typical of Parkinson's disease. Participants of the trial reported their experiences and results, highlighting how the 24-hour treatment with ND0612 impacted their motor state transitions based on home diaries.

1. Effect of ND0612 Continuous Infusion on Motor Performance and Experiences of Daily Living in Patients with Parkinson's Disease – Rebecca Vayalumkal, PharmD, RPh; MTPA.
2. Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Daily Motor State Characteristics of Patients with Parkinson's Disease Experiencing Motor Fluctuations – Rebecca Vayalumkal, PharmD, RPh; MTPA.

About ND0612

ND0612 represents a groundbreaking step in Parkinson’s disease therapy, designed as a combination drug-device therapy that ensures a continuous supply of medication, administered through subcutaneous infusion. This promising treatment aims to alleviate the burdens posed by motor fluctuations, enhancing long-term quality of life for patients.

The development of ND0612 is spearheaded by NeuroDerm, Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), reflecting the company's dedication to innovative solutions in the realm of pharmaceutical care.

About Mitsubishi Tanabe Pharma America, Inc.

Based in Jersey City, New Jersey, Mitsubishi Tanabe Pharma America is committed to advancing therapeutic knowledge and commercializing effective treatments for patients in North America. As a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation, MTPA focuses its efforts on developing a robust product pipeline and delivering approved therapies to markets while prioritizing patient needs.

For further details, interested individuals are encouraged to visit MTPA's official website or follow their updates on social media platforms.

News Background

This year's IAPRD gathers global experts to discuss advancements in Parkinson's disease management and care. With patients at the heart of their mission, MTPA’s participation underscores their ongoing engagement in pioneering research efforts that aim to transform the landscape of treatment for neurological disorders.

With these upcoming presentations, Mitsubishi Tanabe Pharma America continues to play a significant role in the continuous quest for improved patient outcomes and the development of precise treatment modalities.